Oncology Articles | Page 2

Adding Dendritic Cell-Based Immunotherapy to Chemo Improves OS in Relapsed Ovarian Cancer
The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.
Quizartinib Data Move FLT3 Inhibition Forward in AML Paradigm
FLT3 inhibition continues to be explored as a therapeutic option for patients with FLT3-mutant acute myeloid leukemia, with quizartinib at the forefront following intriguing results of the phase III QuANTUM-R trial.
Progress Made in Locally Advanced Pancreatic Cancer
Dae Won Kim, MD, highlights recent advances in the neoadjuvant and adjuvant settings for patients with localized pancreatic cancer.
Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge
Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.
Richard Kim, MD, discusses the therapeutic landscape of advanced hepatocellular carcinoma in light of recent findings and highlighted anticipated research in the field.
Chemokine Offers Tempting Target in Tumor Niche
Chemokine receptor type 2, a major recruiter of circulating monocytes that subsequently develop into a protumoral type of macrophage within the tumor microenvironment, has emerged as a promising therapeutic target.
The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Neratinib Shows Promise in HER2-Mutant Cervical Cancer
Treatment with neratinib led to a clinical benefit rate of 54.5% in patients with HER2-mutant cervical cancer.
Atezolizumab Shows Comparable Real-World Tolerability, Efficacy in Urothelial Carcinoma
Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma, including clinically relevant subgroups reflective of real-world clinical practice.
Rini Discusses Future of Tivozanib, TKI/Immunotherapy Combos in mRCC
Brian I. Rini, MD, discusses the next steps with tivozanib (Fotivda) and immunotherapy/TKI combinations in patients with metastatic renal cell carcinoma.
Publication Bottom Border
Border Publication